Home › Compare › PAVMZ vs FCPT

PAVMZ vs FCPT: Dividend Comparison 2026

PAVMZ yields 222222.22% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAVMZ wins by $1.4076447531278624e+30M in total portfolio value
10 years
PAVMZ
PAVMZ
● Live price
222222.22%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4076447531278624e+30M
Annual income
$1,406,399,782,569,334,400,000,000,000,000,000,000.00
Full PAVMZ calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — PAVMZ vs FCPT

📍 PAVMZ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAVMZFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAVMZ + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PAVMZ pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAVMZ
Annual income on $10K today (after 15% tax)
$18,888,888.89/yr
After 10yr DRIP, annual income (after tax)
$1,195,439,815,183,934,200,000,000,000,000,000,000.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, PAVMZ beats the other by $1,195,439,815,183,934,200,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAVMZ + FCPT for your $10,000?

PAVMZ: 50%FCPT: 50%
100% FCPT50/50100% PAVMZ
Portfolio after 10yr
$7.038223765639312e+29M
Annual income
$703,199,891,284,667,200,000,000,000,000,000,000.00/yr
Blended yield
99.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

PAVMZ
No analyst data
Altman Z
-10.4
Piotroski
4/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAVMZ buys
0
FCPT buys
0
No recent congressional trades found for PAVMZ or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAVMZFCPT
Forward yield222222.22% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$1.4076447531278624e+30M$49.1K ✓
Annual income after 10y$1,406,399,782,569,334,400,000,000,000,000,000,000.00 ✓$5,775.28
Total dividends collected$1.4075632434891558e+30M$24.1K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PAVMZ vs FCPT ($10,000, DRIP)

YearPAVMZ PortfolioPAVMZ Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$22,232,922$22,222,222.22$11,401$700.92+$22.22M → PAVMZ
2$46,198,082,523$46,174,293,296.41$13,064$864.84+$46198.07M → PAVMZ
3$89,718,752,943,223$89,669,320,994,923.30$15,051$1,072.48+$89718752.93M → PAVMZ
4$162,845,393,609,755,680$162,749,394,544,106,430.00$17,442$1,337.22+$162845393609.74M → PAVMZ
5$276,249,735,879,778,500,000$276,075,491,308,616,120,000.00$20,340$1,677.08+$276249735879778.47M → PAVMZ
6$437,989,462,258,048,500,000,000$437,693,875,040,657,100,000,000.00$23,880$2,116.57+$437989462258048512.00M → PAVMZ
7$649,026,142,700,674,900,000,000,000$648,557,493,976,058,700,000,000,000.00$28,241$2,689.36+$649026142700674875392.00M → PAVMZ
8$898,874,153,179,794,200,000,000,000,000$898,179,695,207,104,400,000,000,000,000.00$33,660$3,442.07+$8.988741531797941e+23M → PAVMZ
9$1,163,523,886,474,633,300,000,000,000,000,000$1,162,562,091,130,731,000,000,000,000,000,000.00$40,456$4,439.95+$1.1635238864746333e+27M → PAVMZ
10$1,407,644,753,127,862,300,000,000,000,000,000,000$1,406,399,782,569,334,400,000,000,000,000,000,000.00$49,063$5,775.28+$1.4076447531278624e+30M → PAVMZ

PAVMZ vs FCPT: Complete Analysis 2026

PAVMZ — Stock

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Full PAVMZ Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this PAVMZ vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAVMZ vs SCHDPAVMZ vs JEPIPAVMZ vs OPAVMZ vs KOPAVMZ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.